News

ADOPTION OF AMED STRENGTHENING PROGRAM FOR PHARMACEUTICAL STARTUP ECOSYSTEM

We announces that our "Development of an Innovative Treatment for Myotonic Dystrophy Type 1 by a Sequence--Specific RNA Binding Protein Targeting Pathogenic CUG Repeat RNA" ("EF-210") has been adopted by Japan Agency for Medical Research and Development ("AMED") as a "Strengthening Program for Pharmaceutical Startup Ecosystem" ("the Program").

For more details, please see ADOPTION OF AMED STRENGTHENING PROGRAM FOR PHARMACEUTICAL STARTUP ECOSYSTEM(PDF)